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systematic RTT QA procedures. These measures are 
compulsory for patient safety and quality but also need to be 
balanced with available resources. RTTs, sensitized to this 
issue and due to their position in the RT process, are 
therefore good candidates to become quality managers (QM) 
in a RT department.  
Since 2010, the Belgian national cancer plan has allowed for 
the progressive introduction of quality management systems 
(QMS) within the licensed radiotherapy departments.  
Between 2010 and 2013, the departments have been funded 
in order to hire one FTE QM whose role is to implement a 
QMS in the department in order to improve the processes and 
patient safety within the RT departments. This includes the 
recording and analysis of near-incidents and incidents 
through the PRISMA-RT (Prevention and Recovery Information 
System for Monitoring and Analysis in RadioTherapy) program. 
A short survey carried out in 2014 demonstrated that 41% of 
the hired QMs had a RTT professional background. Although 
lacking some theoretical background, RTTs are well adapted 
for the QM role and, and along with the non-RTT QMs,  are 
successful in implementing QMS within their departments as 
demonstrated by the preliminary results of the national 
clinical auditing program carried out by the Federal College 
of Radiotherapy using the IAEA methodology (QUATRO[1] 
(Quality Assurance Team for Radiation Oncology)).  
Furthermore, all RT QMs have decided to come together to 
form an association known as QMRT.be (Belgian association of 
Quality Managers in RadioTherapy) whose aim is to integrate 
the procedural requirements of a QMS within the clinical 
reality of patient treatment by acting as support system for 
all RT QMs. Since then, this group has been implicated in 
various projects such as PRISMA-RT expert group and QUATRO 
audits.  
 [1] Comprehensive Audits of Radiotherapy Practice: a tool 
for Quality Improvement. IAEA, Vienna, 2007 
(http://www.iaea.org/books). 
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Healthcare is inclining in the western world with growing 
costs. In the Netherlands it is assumed for instance that cost 
may rise from 13% GDP (90 billion euro) towards 30% GDP in 
2030. At the same time the public, patients, governement 
and  insurance companies question the quality of healthcare. 
From that perspective providers are asked to deliver a broad 
and often changing set of quality indicators to the different 
stakeholders to be used in public for ranking, transparancy 
and choosing information. In the “slipstream” of asking 
different indicators, often different levels for quality are 
defined by the stakeholders.  Irrespective of the perspective 
of “the outside” this will not give a proper insight in quality 
of healthcare and is not the way to initiate improvements of 
healthcare. The latter being important while improvement 
always goes with cost reduction. Quality improvement being 
to only proper way to initiate cost efficacy in healthcare.  
From that perspective already 8 years ago the professional 
boards of medical specialists started “clinical registries”. 
Bottom up collecting clinical information with an online  
feedback and nationwide benchmark, so professionals could 
see whether they are underperfoming or not. During the 
years this proved to be a strong improvement tool in all fields 
were clinical registries were implemented.  Development, 
implementation and exploitation of these registries is 
serviced by the Dutch Institute for Clinical Auditing (DICA; 
www.clinicalaudit.nl) a non-profit organisation driven by 
medical professinals.  At this time more than 17 registries are 
serviced by DICA, using strict preconditions regarding privacy, 
ownership , transparancy, autonomy of professional 
organisations etc. At his time existing registries are 
multidisciplinary extended, results are combined with Patient 
Related Outcome Maesurment’s (PROM’s) and financial data. 
In this way improvement of care at affordable costs with 
satisfied patients comes in reach. The next step is to allign 
data sets to come to global comparisons. During the  session 
“Advanced technology assessment; Quality management in an 
era of rapidly evolving radiology technology” more details 
regarding background, preconditions, results and future 
perspectives will be presented.  
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A better understanding of tumour biology has led to the 
development of targeted therapies, in which a drug is 
designed to disrupt a specific biochemical pathway important 
for tumour cell survival or proliferation.  The introduction of 
these drugs into the clinic has shown that patients can vary 
widely in their responses.  Molecular imaging is likely to play 
an increasingly important role in predicting and detecting 
these responses and thus in guiding treatment in individual 
patients [1].  We have been developing methods for 
detecting the early responses of tumours to therapy, 
including metabolic imaging with hyperpolarized 13C-labelled 
substrates, which we have used both to detect treatment 
response and to investigate the tumour microenvironment 
(reviewed in [2-4]).  Exchange of hyperpolarized 13C label 
between lactate and pyruvate [5] and net flux of label 
between glucose and lactate [6] have been shown to 
decrease post-treatment and hyperpolarized [1,4-
13C]fumarate has been shown to detect subsequent cell 
necrosis [7,8].  Tumour pH can be imaged using 
hyperpolarized H13CO3¯ [9] and redox state can be 
determined by monitoring the oxidation and reduction of [1-
13C]ascorbate and [1-13C]dehydroascorbate respectively [10]. 
 More recently we have shown that we can follow, using 
hyperpolarized [1-13C]pyruvate, the progression of pancreatic 
precursor lesions, in a genetically engineered mouse model of 
the disease, which potentially could be used clinically to 
guide earlier intervention. 
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Purpose: To review the current status of hypoxia PET 
imaging for delineating hypoxic volumes (HVs) inside the 
gross target volume (GTV) and for radiotherapy (RT) outcome 
prediction. 
Methods: Hypoxia PET tracers currently used in clinical trials 
are mainly [18F]-FMISO, [18F]-FAZA and [18F]-HX4. Different 
image acquisition protocols and methods for delineating HVs 
will be presented in this talk. Furthermore, results of recent 
clinical trials will be reviewed where the prognostic value of 
hypoxia PET imaging before and during RT with respect to 
outcome as investigated. 
In our institution, a clinical phase II trial is currently carried 
out where to date n=33 head and neck cancer patients were 
included. Patients were examined using dynamic FMISO PET 
imaging plus conventional FDG PET imaging in addition to 
planning CT and eventually MRI before the start of RT. HVs 
were segmented based on parameters derived from the 
pharmaco-kinetic analysis of the dynamic FMISO PET data. 
Patients were randomized into two treatment arms. Patients 
in the experimental arm were treated with a 10% dose 
escalation to the HV whereas patients in the control arm 
received standard IMRT treatment with 70 Gy in 35 fractions.  
Results: Different manual and (semi-)automatic methods for 
HV delineation based on hypoxia PET data have been used in 
clinical studies, such as thresholding, tumour-to-background 
ratio (TBR) based methods, advanced automatic methods or 
delineations based on dynamic PET imaging. Different 
contouring techniques for HV definition may result in strongly 
varying volumes. Recently published clinical trials confirm 
the prognostic character of hypoxia PET imaging. However, 
no consensus was found yet with regard to the timing of the 
hypoxia PET examination. Some studies found that pre-
treatment hypoxia PET information was correlated to 
outcome whereas others stated that hypoxia PET data 
acquired two weeks into RT had prognostic value. 
For our hypoxia dose painting trial, a planned interim analysis 
was carried out after recruiting n=20 patients. Median follow-
up time for this group was 36 (11 - 52) months. 5 patients did 
not show any tumour hypoxia (HV = 0 mL). The mean HV of 
the hypoxic tumours was 8.6 mL (0.3 – 49.2 mL). 
Furthermore, data acquired in this study could confirm a 
prognostic model relating TCP to a measure derived from 
dynamic FMISO PET imaging acquired before the start of RT. 
Conclusion: Hypoxia PET imaging is a very promising tool for 
the stratification of patients into different risk groups and 
thus a potentially very interesting molecular marker in the 
advent of biologically adapted, personalized RT. However, a 
comparison of results from different clinical trials is difficult 
due to large discrepancies in terms of imaging protocols and 
data analysis strategies. 
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Pre-RT MR spectroscopic imaging ( MRSI) has been described 
as a promising non invasive tool to depict GBM behaviour and 
extension. 
We confirmed this based on data from an in-house 
prospective clinical trial for GBM, analysing both pre and 
relapse MRSI and published the predctive value of Cho/NAA>2 
( CNR2) regions for the site of relapse .  We then elaborated 
a dose-painting clinical trial aiming to increase dose to CNR2 
regions on biopsied or resected glioblastoma. 
First, as MR spectroscopy metabolic maps are not delivered in 
a DICOM format, we developed an automated image 
processing tool for MR  spectroscopy data integration onto 
planning CT. 
Then we performed a dosimetric study for each patient, 
comparing doses to organs at risk with three different 
treatments : 1) with conventional 3D RT at 60 Gy / 2 Gy 
fractions targeted to contrast enhancement, CE + 2cm ) same 
treatment with an addition SIB IMRT, Simultaneous Integrated 
Boost with Intensity Modulated RadioTherapy ( i.e. 2.4 Gy by 
fraction on the boost), the boost being the MR spectroscopy 
abnormalities ( Cho/NAA ratio>2 + 1cm)  3) SIB IMRT targeted 
to MR Spectroscopy abnormalities + contrast enhancement + 
3mm . Then the V10 Gy and V40 Gy to normal brain and V54 
to brainstem were compared. The dosimetric comparaison 
showed that the doses to organs at risk were lower with 
increased dose SIB IMRT 72 Gy than with standard 60 Gy 
conventional RT and equivalent to 60 Gy IMRT.  The size of 
the SIB could be increased to spectral abnormalities + 
contrast enhancement without increasing dose to organs at 
risk. 
Finally,  we started in 2011 a prospective  phase III 
randomized clinical trial SPECTRO GLIO, financed by the 
French national Cancer Institute ( INCa). The goal is the 
inclusion of 220 patients treated in 9 french centers.  
Standard treatment delivers 60 GY+ Temozolomide, targeted 
to CE+2cm;  patients included in the experimental arm 
receive an additional 72Gy SIB targeted to MRSI 
abnormalities+1cm and to Contrast enhancement. The 
endpoint is survival. 
This ongoing trial includes a centralized MR spectroscopy 
post-treatment  and CHO/NAA>2 maps integration to planning 
CT . Target volumes and Organs at risk delineation are also 
centralized at our institution for all participating centers.  
An external online quality control of the dosimetry is 
performed for each patient included in the experimental 
arm. 
Patients undergo MRI and MRSI before and every two months 
after RT, as well as MR perfusion and diffusion.  
We  recently published a preliminary study of Lactate on 
MRSI, as lactate is a surrogate of tumor hypoxia and 
radioresistance.  We defined a lactate/NAA>0.4  threshold , 
having a  predictive value for the site of relapse. This data 
will have to be confirmed on the larger set of data from the 
Spectro GLio trial as well as MR diffusion and perfusion that 
are performed longitudinally in this trial.  
Conclusion: In our talk we will describe the different steps of 
a dose-painting clinical trial based on metabolic imaging with 
MRSI in GBM: 
-        study of  the predictive value for the site of relapse of 
GBM  
-        developping a quantification and integration method of 
the metabolic maps into planning CT 
